![]() |
Patrice Cacoub 1, 2, 3
Auteur
Pierre Nahon 4, 5
Auteur
Richard Layese 6, 7
Auteur
Lorraine Blaise 5
Auteur
Anne Claire Desbois 1, 2, 3
Auteur
Valérie Bourcier 5, 8
Auteur
Carole Cagnot 9
Auteur
Patrick Marcellin 10
Auteur
Dominique Guyader 11
Auteur
Stanislas Pol 12, 13, 14
Auteur
Dominique Larrey 15, 16
Auteur
Victor de Ledinghen 17
Auteur
Jean-Pierre Bronowicki
Auteur
Jean-Pierre Zarski 22
Auteur
Ghassan Riachi 23
Auteur
Paul Calès 24
Auteur
Jean-Marie Péron 25
Auteur
Laurent Alric 26
Auteur
Marc Bourlière 27
Auteur
Philippe Mathurin 28
Auteur
Jean-Frédéric Blanc 29
Auteur
Armand Abergel 30
Auteur
Lawrence Serfaty 31
Auteur
Ariane Mallat 32
Auteur
Jean-Didier Grangé 33
Auteur
Pierre Attali 34
Auteur
Yannick Bacq 35
Auteur
Claire Wartelle 36
Auteur
Thong Dao 37
Auteur
Dominique Thabut 38, 1
Auteur
Christophe Pilette 39
Auteur
Christine Silvain 40
Auteur
Christos Christidis 41
Auteur
Dominique Capron 42
Auteur
Gérard Thiefin 43
Auteur
David Zucman 44
Auteur
Vincent Di Martino 45
Auteur
Corinne Isnard Bagnis 1, 46
Auteur
Marianne Ziol 4, 5
Auteur
Angela Sutton 5
Auteur
Eric Letouze 4
Auteur
Françoise Roudot-Thoraval 7, 6
Auteur
Etienne Audureau 6, 7
Auteur
Anrs Co12 Cirvir Group
Auteur
BACKGROUND: The objective was to examine the role of a sustained virological response (SVR) on major adverse cardiovascular events (MACEs) in patients with compensated hepatitis C virus (HCV) cirrhosis.
METHODS: Patients with the following criteria were enrolled in 35 French centers: (1) biopsy-proven HCV cirrhosis; (2) Child-Pugh A; (3) positive viremia; and (4) no prior liver complication, and then prospectively followed. All patients received HCV treatment after inclusion. MACEs included stroke, myocardial infarction, ischemic heart disease, heart failure, peripheral arterial disease, cardiac arrest, and cardiovascular death. SVR, defined as negative viremia 12 weeks posttreatment, was considered as a time-dependent covariate, and its effect on MACE occurrence was assessed. The median follow up was 57.5 months, ending in December 2015.
RESULTS: Sixty-two of 878 (7.1%) patients presented a total of 79 MACEs. The main predictive baseline factors of MACEs were Asian ethnic origin, history of MACEs, arterial hypertension, diabetes mellitus, current smoking, low serum albumin level, high total bilirubin level, and low platelet count. In multivariate analysis, SVR was associated with a decreased risk of MACEs (hazard ratio=0.35, 95% CI 0.09-0.97, P=.044), whereas Asian ethnic origin, arterial hypertension, smoking, and low serum albumin level remained predictive of MACE occurrence. The 5-year survival rate was 60.1% versus 87.5% in patients who did versus those who did not present a MACE (P<.001).
CONCLUSIONS: In patients with compensated HCV-related cirrhosis, Asian ethnic origin, arterial hypertension, smoking, and low serum albumin are independent predictive factors of cardiovascular events, whereas an SVR is associated with a decreased rate of cardiovascular events.
UNIV-ANGERS | UNIV-TLSE3 | I3 | UPEC-UPEM | UPEC | COMUE-NORMANDIE | UNIV-MONTPELLIER | UNIV-COTEDAZUR | UNIROUEN | UNIV-AMU | UNICAEN | SU-MEDECINE | CNRS | SORBONNE-PARIS-NORD | UNIV-PARIS13 | BS | UNIV-PARIS5 | UNIV-PARIS7 | USPC | SORBONNE-UNIVERSITE | UNIV-PARIS | PASTEUR | UNAM | IRD | PHARMA-DEV | UGA | C3M | INC-CNRS | HCL | CHLS